Related Experiment Video
Updated: May 28, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
High-density lipoprotein levels and risk of cardiovascular events: a review
Gian Francesco Mureddu1, Filippo Brandimarte, Leonardo De Luca
1Echocardiography Laboratory and Cardiovascular Prevention Unit, San Giovanni-Addolorata Community Hospital, Rome, Italy. mureddu.gianfra@gmail.com
Insights
High-density lipoprotein cholesterol (HDL-C) is a key predictor of cardiovascular events, independent of other risk factors. While raising HDL-C shows promise, current treatments lack definitive proof of cardiovascular outcome reduction independent of LDL-C changes.
Area of Science:
- Cardiology
- Lipid Metabolism
- Preventive Medicine
Background:
- High-density lipoprotein cholesterol (HDL-C) is a significant independent predictor of cardiovascular events.
- The inverse relationship between HDL-C and cardiovascular risk is continuous and independent of factors like blood pressure, smoking, and BMI.
- Residual cardiovascular risk persists even with low-density lipoprotein cholesterol (LDL-C) below guideline targets, highlighting HDL-C's importance.
Purpose of the Study:
- To review the role of HDL-C in cardiovascular disease risk.
- To evaluate the efficacy of treatments aimed at increasing HDL-C levels for cardiovascular event reduction.
- To identify gaps in current understanding and therapeutic strategies related to HDL-C.
Main Methods:
- Literature review of studies on HDL-C, cardiovascular risk, and lipid-lowering therapies.
- Analysis of clinical trial data and epidemiological studies.
- Evaluation of pharmacological interventions targeting HDL-C.
Main Results:
- HDL-C levels strongly correlate with atherosclerosis progression and cardiovascular disease risk.
- Treatments increasing HDL-C have shown potential in reducing cardiovascular disease incidence.
- Pharmacological evidence for HDL-C-raising therapies independently reducing cardiovascular outcomes is not fully established.
Conclusions:
- Current guidelines do not target HDL-C levels specifically due to incomplete evidence on independent outcome benefits.
- Statins have limited impact on HDL-C; fibrates yield inconclusive results; niacin has side effects.
- Further research is essential to explore novel compounds for raising HDL-C or modifying its function for cardiovascular protection.
Abstract:
High-density lipoprotein cholesterol (HDL-C) is a strong and independent predictor of major cardiovascular events in a wide range of patients. The relationship between HDL-C cholesterol and cardiovascular risk appears to be linear, continuous, negative and independent of other risk factors such as blood pressure, smoking and BMI. In addition, the inverse relationship between HDL-C and cardiovascular events does not depend on low-density lipoprotein cholesterol (LDL-C) levels, so a substantial residual cardiovascular risk is maintained also in individuals with LDL-C levels below the target recommended by scientific guidelines. Furthermore, a strong relationship among HDL-C levels, progression of atherosclerosis and risk of cardiovascular diseases has been also demonstrated. Treatments that increase HDL-C levels have been shown to be effective in reducing incidence of cardiovascular diseases both in primary and secondary prevention settings. However, proof that increasing HDL-C levels by pharmacological treatment is able to confer a reduction in major cardiovascular outcomes independent of changes in LDL-C or triglycerides levels is not completely defined. Among currently available compounds, statins do not seems to have a sufficient effect on HDL-C profile. Studies on fibrates have shown inconclusive results. Although niacin has been demonstrated to reduce the incidence of major cardiovascular events paralleling the regression of atherosclerosis, significant side-effects still limit its use. The potential benefit of cholesterol ester transfer protein inhibition is still under investigation. The combination therapy of fibrates with statins is also controversial. Thus, despite the potentially favorable effect of raising HDL-C levels, the available guidelines still do not consider HDL-C levels as a specific target for therapy. Further studies are needed to assess the role of new compounds to raise HDL-C levels or modify HDL composition and functionality.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management
Cholesterol: Significance and Regulation
Considering cholesterol and...
Atherosclerosis I: Introduction
Lipids: Dietary Sources and Requirements